NASDAQ:EXELExelixis Stock Price, Forecast & News

$24.71

+0.38 (+1.56 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$23.87

Now: $24.71▼

$24.78

50-Day Range

$17.78

MA: $23.75▼

$27.42

52-Week Range

$13.67

Now: $24.71▼

$27.80

Volume2.85 million shs

Average Volume3.26 million shs

Market Capitalization$7.58 billion

P/E Ratio26.57

Dividend YieldN/A

Beta1.54

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. Exelixis, Inc. has collaboration and license agreement with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Invenra, Inc., StemSynergy Therapeutics, Inc., and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Exelixis has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $28.58, Exelixis has a potential upside of 15.7% from its current price of $24.71.
Amount of Analyst Coverage
Exelixis has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Exelixis has received 494 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Exelixis has received 448 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Exelixis has received 52.44% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote “Outperform” if you believe EXEL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Exelixis does not currently pay a dividend.
Dividend Growth
Exelixis does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Exelixis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,460,794.00 in company stock.
Percentage Held by Insiders
Only 4.50% of the stock of Exelixis is held by insiders.
Percentage Held by Institutions
79.99% of the stock of Exelixis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9 Earnings and Valuation

Earnings Growth
Earnings for Exelixis are expected to grow by 79.55% in the coming year, from $0.44 to $0.79 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Exelixis is 26.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.78.
Price to Earnings Ratio vs. Sector
The P/E ratio of Exelixis is 26.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.78.
Price to Earnings Growth Ratio
Exelixis has a PEG Ratio of 1.48. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Exelixis has a P/B Ratio of 4.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.77 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Commercial physical research

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:EXEL

Previous Symbol

CUSIP30161Q10

CIK939767

Webwww.exelixis.com

Phone650-837-7000

Debt

Debt-to-Equity RatioN/A

Current Ratio8.09

Quick Ratio7.98

Price-To-Earnings

Trailing P/E Ratio26.57

Forward P/E Ratio56.16

P/E Growth1.48

Sales & Book Value

Annual Sales$967.78 million

Price / Sales7.83

Cash Flow$1.10 per share

Price / Cash Flow22.44

Book Value$5.70 per share

Price / Book4.34

Profitability

EPS (Most Recent Fiscal Year)$1.02

Net Income$321.01 million

Net Margins30.01%

Return on Equity18.01%

Return on Assets16.17%

Miscellaneous

Employees484

Outstanding Shares306,660,000

Market Cap$7.58 billion

Next Earnings Date7/29/2020 (Estimated)

OptionableOptionable

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

How has Exelixis' stock been impacted by COVID-19 (Coronavirus)?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EXEL stock has increased by 42.7% and is now trading at $24.71. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Exelixis?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Exelixis.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Exelixis.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its earnings results on Tuesday, May, 5th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.13 by $0.02. The biotechnology company earned $226.90 million during the quarter, compared to the consensus estimate of $216.64 million. Exelixis had a return on equity of 18.01% and a net margin of 30.01%. Exelixis's revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the business posted $0.27 earnings per share. View Exelixis' earnings history.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, May, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $850-900 million, compared to the consensus revenue estimate of $886.93 million.

What price target have analysts set for EXEL?

12 brokerages have issued 1 year price targets for Exelixis' shares. Their forecasts range from $21.00 to $40.00. On average, they expect Exelixis' share price to reach $28.58 in the next twelve months. This suggests a possible upside of 15.7% from the stock's current price. View analysts' price targets for Exelixis.

Has Exelixis been receiving favorable news coverage?

Media stories about EXEL stock have been trending very negative on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exelixis earned a news sentiment score of -3.7 on InfoTrie's scale. They also gave news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutExelixis.

Are investors shorting Exelixis?

Exelixis saw a drop in short interest during the month of May. As of May 15th, there was short interest totaling 16,450,000 shares, a drop of 16.9% from the April 30th total of 19,790,000 shares. Based on an average daily trading volume, of 4,220,000 shares, the days-to-cover ratio is presently 3.9 days. Approximately 5.6% of the company's stock are sold short. View Exelixis' Current Options Chain.

Who are some of Exelixis' key competitors?

Some companies that are related to Exelixis include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

Who are Exelixis' key executives?

Exelixis' management team includes the following people:

Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.90%), Meditor Group Ltd (4.72%), State Street Corp (3.70%), JPMorgan Chase & Co. (2.78%), AQR Capital Management LLC (1.81%) and First Trust Advisors LP (1.63%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View institutional ownership trends for Exelixis.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, BlackRock Inc., Nuveen Asset Management LLC, Meditor Group Ltd, Orbimed Advisors LLC, Squarepoint Ops LLC, Bank of New York Mellon Corp, and Principal Financial Group Inc.. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi. View insider buying and selling activity for Exelixis.

Which institutional investors are buying Exelixis stock?

EXEL stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Janus Henderson Group PLC, Blair William & Co. IL, Samlyn Capital LLC, JPMorgan Chase & Co., First Trust Advisors LP, MERIAN GLOBAL INVESTORS UK Ltd, and Mackay Shields LLC. View insider buying and selling activity for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $24.71.

How big of a company is Exelixis?

Exelixis has a market capitalization of $7.58 billion and generates $967.78 million in revenue each year. The biotechnology company earns $321.01 million in net income (profit) each year or $1.02 on an earnings per share basis. Exelixis employs 484 workers across the globe.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff